Initiating Immunotherapy in the Treatment of Stage IV Cancers in the Month Before Death—A Health Care Disparities Lens
Menée aux Etats-Unis à partir de données portant sur 242 371 patients atteints d'un cancer métastatique (âge moyen : 67,9 ans ; durée moyenne de suivi : 13,7 mois), cette étude de cohorte rétrospective analyse les facteurs associés à l'utilisation d'immunothérapies en fin de vie (début du traitement dans le mois précédant le décès)
Approximately 600 000 people in the US were anticipated to die of cancer in 2023, and differences in screening, diagnosis, treatment, and mortality vary across health care centers. In their cohort study in this issue of JAMA Oncology, Kerekes and colleagues show that immunotherapy is being increasingly initiated in the month before death in the treatment of stage IV cancers, that this practice is more common at nonacademic and lower-volume health care centers, and that such centers have worse 5-year survival rates. This Editorial highlights the strengths and future directions of this research through a health care disparities lens.
JAMA Oncology 2024